Inovio Pharmaceuticals (NASDAQ:INO) Rating Lowered to Underp

Bank of America cut shares of Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) from a neutral rating to an underperform rating in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has $2.00 price objective on the biopharmaceutical company’s stock. INO has been the topic of several other research reports. Royal […]

Related Keywords

United States , Canada , America , Davidb Weiner , , Northern Trust Corp , Rafferty Asset Management , Analyst Recommendations For Inovio Pharmaceuticals , Inovio Pharmaceuticals Inc , Institutional Trading Of Inovio Pharmaceuticals , Vanguard Group Inc , Inovio Pharmaceuticals Stock Down , News Ratings For Inovio Pharmaceuticals Daily , Cantor Fitzgerald , Inovio Pharmaceuticals , Royal Bank , Get Rating , Marketbeat Ratings , Pharmaceuticals Stock Down , Director David , Street Corp , Asset Management , Trust Corp , Inovio Pharmaceuticals Daily , Nasdaq Ino , Ino , Medical , Downgrade , Bank Of America Co ,